You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 8,563,563


✉ Email this page to a colleague

« Back to Dashboard


Title:Inhibitors of bruton's tyrosine kinase
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Filing Date:Jan 30, 2012
Application Number:13/361,730
Claims:1. A method for treating a B-cell proliferative disorder in a subject in need thereof comprising administering to the subject two or more agents, wherein the first agent is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) and the second agent is an anti-cancer drug, wherein the irreversible inhibitor is a compound having the structure of Formula (A): ##STR00058## wherein: A is N; R.sub.1 is phenyl-O-phenyl or phenyl-S-phenyl; R.sub.2 and R.sub.3 are independently H; R.sub.4 is L.sub.3-X-L.sub.4-G, wherein, L.sub.3 is optional, and when present is an optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted alkenyl, optionally substituted or unsubstituted alkynyl; X is optional, and when present is O, --C(.dbd.O), S, --S(.dbd.O), --S(.dbd.O).sub.2, --NH, --NR.sub.9, --NHC(O), --C(O)NH, --NR.sub.9C(O), --C(O)NR.sub.9, --S(.dbd.O).sub.2NH, --NHS(.dbd.O).sub.2, --S(.dbd.O).sub.2NR.sub.9--,--NR.sub.9S(.dbd.O).sub.2, --OC(O)NH--, --NHC(O)O--, --OC(O)NR.sub.9--, --NR.sub.9C(O)O--, --CH.dbd.NO--, --ON.dbd.CH--, --NR.sub.10C(O)NR.sub.10--, heteroaryl, aryl, --NR.sub.10C(.dbd.NR.sub.11)NR.sub.10--, --NR.sub.10C(.dbd.NR.sub.11)--, --C(.dbd.NR.sub.11)NR.sub.10--, --OC(.dbd.NR.sub.11)--, or --C(.dbd.NR.sub.11)O--; L.sub.4 is optional, and when present is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle; or L.sub.3, X and L.sub.4 taken together form a nitrogen containing heterocyclic ring; G is ##STR00059## wherein, R.sub.6 R.sub.7 and R.sub.8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; each R.sub.9 is independently selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl; each R.sub.10 is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl; or two R.sub.10 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or R.sub.11 and R.sub.10 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; and each R.sub.11 is independently selected from H, --S(.dbd.O).sub.2R.sub.8, --S(.dbd.O).sub.2NH.sub.2, --C(O)R.sub.8, --CN, --NO.sub.2, heteroaryl, or heteroalkyl; or pharmaceutically acceptable salts thereof.

2. The method of claim 1, wherein the B-cell proliferative disorder is a lymphoma.

3. The method of claim 1, wherein the B-cell proliferative disorder is selected from nodal marginal zone B cell lymphoma, extranodal marginal zone B cell lymphoma, splenic marginal zone B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, and burkitt lymphoma.

4. The method of claim 1, wherein the B-cell proliferative disorder is plasma cell myeloma.

5. The method of claim 1, wherein the B-cell proliferative disorder is a leukemia.

6. The method of claim 1, wherein the B-cell proliferative disorder is selected from B-cell prolymphocytic leukemia and Burkitt leukemia.

7. The method of claim 1, wherein the anti-cancer drug is a proapoptotic agent, angiogenesis inhibitor, dexamethasone, or a combination thereof.

8. The method of claim 1, wherein the anti-cancer drug is a proapoptotic agent.

9. The method of claim 1, wherein the anti-cancer drug is an angiogenesis inhibitor.

10. The method of claim 1, wherein the anti-cancer drug is dexamethasone.

11. The method of claim 1, wherein the irreversible inhibitor of Btk and the anti-cancer drug are administered simultaneously.

12. The method of claim 1, wherein the irreversible inhibitor of Btk and the anti-cancer drug are administered sequentially.

13. The method of claim 1, wherein the irreversible inhibitor of Btk is administered orally.

14. A method for treating a plasma cell myeloma in a subject in need thereof comprising administering to the subject two or more agents, wherein the first agent is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) and the second agent is an agent for treating plasma cell myeloma, wherein the irreversible inhibitor is a compound having the structure of Formula (A): ##STR00060## wherein: A is N: R.sub.1 is phenyl-O-phenyl or phenyl-S-phenyl; R.sub.2 and R.sub.3 are independently H; R.sub.4 is L.sub.3-X-L.sub.4-G, wherein, L.sub.3 is optional, and when present is an optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted alkenyl, optionally substituted or unsubstituted alkynyl; X is optional, and when present is O, --C(.dbd.O), S, --S(.dbd.O), --S(.dbd.O).sub.2, --NH, --NR.sub.9, --NHC(O), --C(O)NH, --NR.sub.9C(O), --C(O)NR.sub.9, --S(.dbd.O).sub.2NH, --NHS(.dbd.O).sub.2, --S(.dbd.O).sub.2NR.sub.9--, --NR.sub.9S(.dbd.O).sub.2, --OC(O)NH--, --NHC(O)O--, --OC(O)NR.sub.9--, --NR.sub.9C(O)O--, --CH.dbd.NO--, --ON.dbd.CH--, --NR.sub.10C(O)NR.sub.10--, heteroaryl, aryl, --NR.sub.10C(.dbd.NR.sub.11)NR.sub.10--, --NR.sub.10C(.dbd.NR.sub.11)--, --C(.dbd.NR.sub.11)NR.sub.10--, --OC(.dbd.NR.sub.11)--, or --C(.dbd.NR.sub.11)O--; L.sub.4 is optional, and when present is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle; or L.sub.3, X and L.sub.4 taken together form a nitrogen containing heterocyclic ring; G is ##STR00061## wherein, R.sub.6 ,R.sub.7 and R.sub.8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; each R.sub.9 is independently selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl; each R.sub.10 is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl; or two R.sub.10 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or R.sub.11 and R.sub.10 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; and each R.sub.11 is independently selected from H, --S(.dbd.O).sub.2R.sub.8, --S(.dbd.O).sub.2NH.sub.2, --C(O)R.sub.8, --CN, --NO.sub.2, heteroaryl, or heteroalkyl; or pharmaceutically acceptable salts thereof.

15. The method of claim 1 wherein L.sub.3, X and L.sub.4 taken together form a nitrogen containing heterocyclic ring.

16. The method of claim 1 wherein G is ##STR00062##

17. The method of claim 1 wherein R.sub.6, R.sub.7, and R.sub.8 are each independently H.

18. The method of claim 1 wherein the compound has the structure ##STR00063##

19. A method for treating a B-cell proliferative disorder in a subject in need thereof comprising administering to the subject two or more agents, wherein the first agent is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) and the second agent is an anti-cancer drug, wherein the selective, covalent inhibitor is a compound having the structure of ##STR00064## or a pharmaceutically acceptable salt thereof.

20. The method of claim 14 wherein the compound has the structure ##STR00065## or a pharmaceutically acceptable salt thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.